NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1
NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma
NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma
NCT05066646: Phase 1/2: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in RRMM
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma